UOC
PRTK

UBS O'Connor’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

UBS O'Connor’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-40,000
Closed -$556K – 515
2016
Q2 		$556K Buy
+40,000
New +$589K 0.01% 336

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

UBS O'Connor's PRTK Position: Q3 2016 in Review

UBS O'Connor sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2016, closing a stake of 40,000 shares — an estimated $556K sold.

UBS O'Connor first reported a position in PRTK in Q2 2016 and held it in 1 quarter. The position peaked at $556K in Q2 2016. 86 funds tracked by Wall St. Rank hold PRTK as of Q3 2016.

  • UBS O'Connor reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • UBS O'Connor sold 40,000 Paratek Pharmaceuticals, Inc. shares in Q3 2016, an estimated $556K.
  • UBS O'Connor first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2016 and held it in 1 quarter.
  • UBS O'Connor's Paratek Pharmaceuticals, Inc. position peaked at $556K in Q2 2016.
  • 86 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2016.

Based on UBS O'Connor's 13F filing for Q3 2016, filed 14 Nov 2016.